falsefalse

Dr Janjigian on PROs for Perioperative Durvalumab Plus FLOT in Gastric/GEJ Adenocarcinoma

Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    “Patient-reported outcomes and quality of life [were] the same in both groups [for durvalumab plus FLOT and FLOT alone], once again highlighting the feasibility of this regimen as [a potential] new standard globally for [resectable] gastric and gastroesophageal adenocarcinoma.”

    Yelena Y. Janjigian, MD, chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, provided updated data from the phase 3 MATTERHORN trial (NCT04592913) at 2025 ESMO Gastrointestinal Cancers Annual Congress focused on patient-reported outcomes (PROs) and quality-of-life (QOL) assessments in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma receiving perioperative durvalumab (Imfinzi) plus FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) or placebo plus FLOT.

    Data presented at the Congress showed that patients treated with durvalumab plus FLOT (n = 467) did not experienced a clinically meaningful deterioration in global health score (GHS)/QOL, physical function, or role function at 3 months following the completion of treatment compared with those given placebo plus FLOT (n = 459).

    Janjigian emphasized that the addition of durvalumab did not adversely affect surgical eligibility or chemotherapy delivery. Rates of surgery completion remained consistent across both arms, and the R0 resection rates were 92% in both groups. Moreover, the FLOT regimen remained feasible on a global scale regardless of immunotherapy administration, she noted. No new or unexpected toxicities were observed with the combination, and PRO measures and overall QOL remained comparable between treatment arms throughout the perioperative course. These data, along with the previously reported efficacy findings, help support perioperative durvalumab plus FLOT as a new potential standard of care for patients with resectable gastric/GEJ adenocarcinoma, she said.

    The updated analysis also underscored the broad applicability of the treatment regimen across a wide age spectrum. The study included patients as young as 26 years of age, reflecting the increasing incidence of upper gastrointestinal cancers in younger populations, Janjigian said. Importantly, efficacy and safety were also preserved in patients 65 years of age and older, with subgroup analyses demonstrating consistent treatment effects across all prespecified subgroups. Janjigian emphasized the importance of functional status over chronological age when evaluating fitness for perioperative FLOT-based therapy.

    In clinical practice, Janjigian noted that up-front chemotherapy dose adjustments to mitigate toxicity—particularly reductions in docetaxel and oxaliplatin—can be considered based on baseline performance status and comorbidities. She highlighted the value of tailoring initial chemotherapy dosing to the individual patient, such as omitting leucovorin or initiating treatment at a 20% dose reduction when appropriate. This approach may optimize tolerability and preserve therapeutic intent with triplet chemotherapy, she concluded.


    x